6th Annual Biologics Manufacturing Asia

CPhI Worldwide

The Annual Biologics Manufacturing Asia, 400+ biomanufacturing stakeholders from BIG Pharma, Biopharma, Contract Manufacturing Organisations, Academic & Research Institutes, Regulatory Authorities across Singapore, South Korea, Taiwan, Japan, Australia, India, Indonesia, Malaysia,  and China  will convene on the best manufacturing practices in order to have access to faster, cheaper and better biologic drugs!

Increase viable CHO cell density by supplementation with recombinant Insulin Human AF

CHO cells are one of the most widely used platforms for the production of biopharmaceuticals. Increased demand for safety and reliability has moved the standard for CHO cell culture media
from Serum to Serum free and further on to chemically defined media. UAB in collaboration with Novo Nordisk Pharmatech (world’s largest supplier of recombinant insulin) has shown
that addition of animal origin free insulin to three leading commercially available off-the-shelf chemically defined media resulted in significant increases in viable cell density. In addition to
this benefit insulin has been proven to aid in the expression of difficult to express proteins.

Read the full study

Read more about our Insulin Human AF or contact us.



Vanessa León

International Marketing Manager


Direct phone: +45 4042 6284